Introduction {#s1}
============

A Brief Overview of Lung Circulatory System {#s1_1}
-------------------------------------------

The lung is a metabolic organ with unique circulatory system. It has two types of blood circulation: 1) pulmonary circulation that is responsible for gas exchange and 2) bronchial circulation (called pulmonary collateral circulation, systemic circulation) that carries oxygenated blood to the bronchi and trachea, extra pulmonary and intra pulmonary airways, nerves and lymph nodes. Pulmonary arteries have thinner walls without basal tone and with less vascular smooth muscle compared to other arteries. Factors that affect lung circulation are vascular structure, hormonal and neuronal agents and oxygen uptake from the environment. The most important function of the pulmonary circulation is gas exchange to provide blood-containing oxygen for organs consumption. CO~2~-rich blood from the right atrium and right ventricle and the pulmonary artery is transferred to the lung for gas exchange; then oxygen-rich blood is transferred *via* pulmonary vein to the left atrium and left ventricle and then delivered to the body through the aortic artery. Bronchial circulation provides oxygen and nutrients for airway wall and inflammatory cells needed for immune response in airway mucosa, and cleaning the airway from inflammatory mediators and infected particles ([@B136]).

Pulmonary Hypertension: General Definition and Epidemiology {#s1_2}
-----------------------------------------------------------

Pulmonary hypertension (PH) is a disease associated with increase in pulmonary vasculature resistance due to increase in vascular tone and remodeling the structure of pulmonary arteries (PAs). PH occurs predominantly in women (80%), over the mean age of 53 years ([@B129]). It has been reported about 100 million people around the world suffering from PH ([@B59]). Approximately every untreated patient with PH could survive for about 2.8 years. Some of the PH symptoms include permanent hypoxia, inflammation of lungs, oxidative stress, increase of proliferation of endothelial cells in pulmonary arteries and inhibition of apoptosis, which leads to pulmonary vascular remodeling ([@B122]).

One of the results of PH is an increase in the volume of pumped blood from the heart and increased pulmonary vasoconstriction to compensate the lack of oxygen in the lungs ([@B117]); when blood volume increased, it leads to increased right ventricular pressure and right ventricular hypertrophy and finally leads to right ventricular failure ([@B65]). Increase the pulmonary arterial pressure leads to right ventricle hypertrophy (RV/TV ratios) and increase circulating blood volume of the lungs, compared to normal conditions. Rapid blood flow moving through the lungs vasculature causes disturbance in O~2~ and CO~2~ exchange ([@B112]).

The most important indexes for PH are fatigue and dyspnea during walking or moderate physical activity. The inability to do daily functions in these people leads to decrease their quality of life. PH is difficult to diagnose because of its similarities of symptoms to the other cardiopulmonary disease; as a result, the disease progresses and leads to increased mortality ([@B11]). The final diagnosis is through clinical assays for the detection of hemodynamic abnormalities. In most patients that suffering from PH, right ventricular hypertrophy is seen in the electrocardiogram and pulmonary function tests, confirm a decrease in lung capacity ([@B39]).

Classification and Etiology {#s1_3}
---------------------------

PH is classified into five groups based on its etiology: i) Hypertension in the pulmonary arteries that lead to pulmonary arterial hypertension (PAH); ii) Left-sided heart failure that leads to PH; iii) Hypoxic pulmonary vasoconstriction that leads to PH; iv) High pressure in the blood vessels of the lungs that leads to chronic thromboembolic pulmonary hypertension (CTEPH), and v) Idiopathic PH (unknown reason).

Many studies suggested the effect of various factors such as high altitude, low temperatures, intense light, air pollution, type of nutrition, oxidative stress and gene mutations on the progression of PH ([@B8]). Based on these studies, the use of antioxidant compounds could be effective in treatment and control of PH ([@B155]).

Approximately 50% of patients suffer from idiopathic PAH. Diverse mutations are responsible for PH including ALK-I, BMPR2, endoglin, and CAV-I ([@B129]) too. Studies have proven the effects of nutrition on the progression of PH, such as calorie intake, amount of minerals and pure proteins ([@B72]). The cellular and molecular reasons presented bellow could explain occurrence of PH.

Cellular/Molecular Changes during PH Progression {#s1_4}
------------------------------------------------

Some of the most important cellular and molecular changes during PH include smooth muscle cells remodeling, uncontrolled proliferation of endothelial cells, inflammation and the presence of proinflammatory cells, platelet aggregation and thrombosis ([@B60]).

### Smooth Muscle Cells and Remodeling {#s1_4_1}

During the progression of PH, smooth muscle cells are remodeling to small peripheral, pulmonary arteries inside the respiratory acinus are observed; in other words, increase of smooth muscle cells of the distal pulmonary arteries, also known as pathological remodeling. The cellular process of this mechanism is incompletely understood. Anyway, during the process, a layer of myofibroblasts and extracellular matrix are created between the endothelium and internal elastic lamina ([@B133]). The first mechanism of fibroblast to media migration is increased expression of matrix metalloproteinases (MMP2 and MMP9). In summary, all the mechanisms involved in these processes lead to increase the thickness and obstruction of the pulmonary arteries ([@B26]).

### Uncontrolled Proliferation of Endothelial Cells {#s1_4_2}

All of the reasons for abnormal proliferation of endothelial cells occur on genetic background, but some of them are due to oxidative stress, hypoxia conditions, inflammation, allergy of drugs or toxins. It has been proven that patients with idiopathic PAH have defects in growth-suppressive genes such as BAX and TGF-β ([@B160]). Approximately 30% of lesions, a mutation in the TGF-βR2 gene and 90% inhibition of expression of TGF-βR2 protein were observed ([@B160]). Studies show that vasculotropic viruses such as human herpesvirus 8 infection could be effective in idiopathic PAH by changing the signaling pathways involved in endothelial cells proliferation ([@B25]). TGF-β1 is an important factor in the process of PH that is associated with endothelial injury and vascular remodeling. Studies suggest that TGF-β1 stimulates the production of ET-1 and that leads to increase of the smooth muscle cells proliferation ([@B132]). Also, TGF-β1 initiates endothelium-smooth muscle transformation ([@B87]).

### Inflammation and Proinflammatory Cells {#s1_4_3}

Inflammatory factors are the important ones in the progression of PH of human and animal models ([@B29]). In some patients, the suppression of the immune system shows positive results in reduction of the inflammation ([@B29]). Also, it has been reported that there are elevation of proinflammatory cytokines (IL-1 and IL-6) levels in patients with idiopathic PH. Histological studies of the lungs confirmed the presence of macrophages and lymphocytes and increased expression of chemokines CCL5 and fractalkine in severe PH ([@B9]).

### Platelets Aggregation and Thrombosis {#s1_4_4}

A notable mechanism in PH progression is thrombosis lesions due to platelet aggregation. This pathway can be initiated by endothelial cells, inflammatory mediators or by the platelets. Blood clot formation in PH patients is characterized by increase of fibrinopeptide A- and D-dimers levels in the plasma. Current studies show that stress itself and pulmonary vascular injury can initiate the process. Other evidence suggests that vascular abnormalities in PH leads to release of procoagulant, vasoactive, and mitogenic mediators by platelets. Some contributing factors in pulmonary vasoconstriction like serotonin, TXA2, TGF-β, AGEPC, PDGF and VPF can be store and release by platelet ([@B49]).

Animal Models {#s1_5}
-------------

Briefly, animal models used in PH studies are divided into several groups according to the type of induction: hypoxia induces PH in mice and rats ([@B114]) and various types of cattle with genetic background ([@B124]); fawn-hooded rat (FHR) that spontaneously develop PH in mild hypoxia conditions ([@B97]); monocrotaline that induces PH by increased inflammation in mice and rats ([@B71]), genetically pulmonary hypertensive rats and mice that develop PH by loss-of-function mutation of *BMPR2* gene in smooth muscle ([@B12]).

Restrictions of Current Treatments of PH {#s1_6}
----------------------------------------

Some of the commonly used drugs for the treatment of PH are phosphodiesterase-5 inhibitors such as sildenafil ([@B110]), prostacyclin analogs such as epoprostenol ([@B130]), and antagonists of endothelin receptor such as bosentan ([@B89]). Some of the effective oral medications include anticlotting drugs, urine-enhancing drugs, oxygen-enhancing drugs, vasorelaxant drugs and calcium channel inhibitors. These treatments improve the quality of life during the first 3 years, but there is no cure for improvement of patient\'s quality of life for 5 years ([@B152]). Also, these cures have not been completely successful because of side effects or incomplete efficacy ([@B60]). Due to the important role of ROS and oxidative stress in PH progression, the intake of antioxidant compounds, which aims to reduce oxidative damage, is one of the notable issues in the treatment of PH ([@B155]).

Methods {#s2}
=======

Study Design {#s2_1}
------------

Electronic databases used in this review study were PubMed, Scopus, and Cochrane library. The keywords used were 'pulmonary hypertension\' in the title/abstract and 'plant\', 'herb\', 'phytochemical\' in the whole text. The period of articles reviewed is between 1979 and 2019. The primary search was performed by two researchers separately, and unrelated articles were separated based on their title and abstract. In the present study, both clinical and animal studies were included in the search but the number of clinical trials were very limited, and therefore the number of the results from the Cochrane library are fewer than these from Scopus and PubMed. Unrelated articles based on title and abstract, non-English and duplicate ones were excluded in the first step, then remaining articles were reviewed in full text. In the second step, several articles were excluded based on the full text. Study design diagram is available in the results section.

Data Extraction {#s2_2}
---------------

All data were extracted and studied by two researchers and were summarized in [**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}. Abstract information of articles, including the name of the plant and the category of phytochemicals, effective dose, the type of PH model, and outcomes of the treatments, were categorized in [**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}. The ↑ and ↓ signs show significant increase and significant decrease respectively of the evaluated factors during the mentioned studies.

###### 

Medicinal plants used for Pulmonary Hypertension treatment.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medicinal plants (Scientific Name)                                                     Effective dose             Extract/Part                    Model                        Animal/Cell                       Outcome                                                                                   References
  -------------------------------------------------------------------------------------- -------------------------- ------------------------------- ---------------------------- --------------------------------- ----------------------------------------------------------------------------------------- ------------
  *Allium macrostemon* Bunge                                                             0.03% mix in food          Volatile oil/Bulb               \_                           *In vitro*-PAECs                  ↑eNOS, ↑Ca^2+^ influx in PAECs                                                            [@B47]

  *Allium sativum* L.                                                                    100 mg/kg                  Aqueous extract/Garlic powder   Hypoxia                      *In vivo*-rat                     ↑NO, ↓PH                                                                                  [@B34]

  *Allium ursinum* L.                                                                    2% mix in food             ND/Leaf                         MCT                          *In vivo*-rat                     ↓RV/(LV + S), ↓MWT %, ↑PDE5A, ↑TAPSE                                                      [@B15]

  *Crataegus rhipidophylla* Gand. (syn. *Crataegus oxyacantha*)                          0.2 mL/L drinking water    Flavonoid enrich extract/ND     High altitude                *In vivo*-broiler chicken         ↑BW, ↓PBP, ↑NO, ↓MDA, ↓hematocrit, ↓H:L ratio, ↓RVH                                       [@B4]

  *Crataegus rhipidophylla* Gand. (syn. *Crataegus oxyacantha*)                          0.2 mL/L drinking water    Extract mix in drinking water   High\                        *In vivo*-broiler chicken         ↓AST, ↓ALT, ↓ALP, ↑Albumin, ↑Globulin,↑Feed intake, ↓RV : TV ratio                        [@B3]
                                                                                                                                                    altitude                                                                                                                                                 

  *Eulophia macrobulbon* (E.C.Parish & Rchb.f.) Hook.f.                                  15 and 450 mg/kg           Ethanolic extract/tuber         MCT                          *In vivo*-rat                     ↑PA relaxation, ↓(RV/LV+S), ↓RVH                                                          [@B154]

  *Kelussia odoratissima* Mozzaf                                                         0.75% mix in food          Mix in food/leaves and shoots   High altitude                *In vivo*-broiler chicken         ↑NO, ↓MDA, ↓H:L ratio, ↓Hematocrit, ↓ET-1, ↑SOD, ↑iNOS                                    [@B2]

  *Mimosa pigra* L.                                                                      *In vivo*: 400 mg/kg\      Hydro methanolic extract/leaf   Hypoxia                      *In vivo*-rat/*In vitro*-HPVECs   ↑NO, ↓PAP, ↓RV/(LV+S), ↓p38, ↓^.^O^-^ ~2,~ ↓TNF-α                                         [@B115]
                                                                                         *In vitro*: 0.01-1 mg/mL                                                                                                                                                                                            

  *Moringa oleifera* Lam.                                                                4.5 mg/kg                  Ethanol extract/leaves          MCT                          *In vivo*-rat                     ↓PABP, ↑SOD                                                                               [@B20]

  *Rhodiola tangutica* (Maxim.) S.H.Fu (syn. *Sedum algidum* var. *tanguticum* Maxim.)   250 mg/kg                  Bioactive enrich fraction       Hypoxia                      *In vivo*-rat                     ↓mPAP, ↓RVH, ↓PCNA, ↓cyclin D1, ↓CDK4, ↑p27Kip1, ↓pulmonary small artery wall thickness   [@B98]

  *Salvia miltiorrhiza* Bunge                                                            14 g/kg                    Aqueous extract/Root            MCT                          *In vivo*-rat                     ↓PAP, ↓ET-1, ↓TXA2, ↑NO, ↑Prostacyclin,\                                                  [@B147]
                                                                                                                                                                                                                   ↓TGF β1, ↓mPAP, ↓RVSP                                                                     

  *Salvia miltiorrhiza*\                                                                 ND                         ND                              Hypoxia                      *In vivo-*rat                     ↓Thickening in the SPAs, ↑HO-1, ↑NO, ↑iNOS, ↓eNOS                                         [@B19]
  Bunge                                                                                                                                                                                                                                                                                                      

  *Salvia miltiorrhiza*\                                                                 0.33 mL/100 g BW           ND                              Hypoxia                      *In vivo*-rat                     ↓RVSP, ↓RVHI                                                                              [@B127]
  Bunge                                                                                                                                                                                                                                                                                                      

  *Securigera securidaca* (L.) Degen & Dörfl.                                            4 g/kg                     Supplementation of diet/seed    High altitude                *In vivo*-broiler chicken         ↑NO, ↓MDA, ↓T, R, S ECG waves, ↓RVH, ↑iNOS, ↑CAT, ↓ET-1                                   [@B5]

  *Terminalia arjuna*\                                                                   250 mg/kg                  Aqueous extract/Stem bark       MCT                          *In vivo*-rat                     ↓SOD, ↑TBARS, ↑CAT, ↓NOX1, ↓BCL2/BAX ratio, ↓%MWT                                         [@B90]
  (Roxb. ex DC.) Wight & Arn.                                                                                                                                                                                                                                                                                

  *Trifolium pretense* L.                                                                20 mg/kg                   Isoflavones                     Low temperature (12 ± 2°C)   *In vivo*-broiler chicken         ↓PAP, ↓ET-1, ↑iNOS                                                                        [@B63]

  *Withania somnifera*\                                                                  100 mg/kg                  Hydro-alcoholic extract/root    MCT                          *In vivo*-rat                     ↓RVP, ↓RVH, ↓ROS, ↓PCNA, ↑procaspase-3, ↑IL-10,\                                          [@B69]
  (L.) Dunal                                                                                                                                                                                                       ↓TNF-α, ↓NF kB, ↓HIF-1α, ↑eNOS                                                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Phytochemicals used for Pulmonary Hypertension treatment.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Phytochemical                        Effective dose                         Model             Animal/cell                                Outcome                                                                                                                                                  References
  ------------------------------------ -------------------------------------- ----------------- ------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Apiin                                5 mM/kg                                Hypoxia           *In vivo*-dog                              ↓PAP, ↓Aortic pressure                                                                                                                                   [@B101]

  Apple polyphenol                     20 mg/kg                               Hypoxia           *In vivo*-rat/*In vitro*-PASMCs            ↓mPAP, ↓PVR, ↓Cytosolic Ca^2+^ in PASMC, ↓Caspase-3, ↓iNOS\                                                                                              [@B55]
                                                                                                                                           ↑NO, ↑eNOS                                                                                                                                               

  Asiaticoside                         50 mg/kg                               Hypoxia           *In vivo*-rat/*In vitro*-HPAECs            ↑NO, ↓ET-1, ↑cGMP, ↑phosphorylation of serine/threonine- protein kinase/eNOS, ↓RVH,↓ mPAP, ↑PI3K/Akt/eNOS pathway                                        [@B150]

  Asiaticoside                         *In vivo*: 50 mg/kg\                   Hypoxia           *In vivo*-rat/*In vitro*-PASMCs            ↓mPAP, ↓RVH, ↓TGF-β1, ↓TGF-βR1, ↓TGF-βR2, ↓Smad2/3                                                                                                       [@B148]
                                       *In vitro*: 100 μg/mL                                                                                                                                                                                                                                        

  Astragalus Polysaccharide            200 mg/kg                              MCT               *In vivo*-rat                              ↓mPAP, ↓PVR, ↓RVH, ↑eNOS, ↑NO, ↓IL-1β, ↓IL-6, ↓TNF-α, ↓pho-IκBα                                                                                          [@B163]

  Baicalin                             30 mg/kg                               Hypoxia           *In vivo*-rat                              ↑ADAMTS-1, ↓Type I collagen, ↓RV/(LV + S)%, ↓ mSAP, ↓mPAP                                                                                                [@B80]

  Baicalein                            10 mg/kg                               MCT               *In vivo*-rat                              ↓RVSP, ↓RVH, ↓ET-1, ↓ET~A~R, ↑SOD, ↓Akt/ERK1/2/GSK3β/β-catenin, ↑eNOS, ↓vWF                                                                              [@B53]

  Baicalin                             40 μg/L                                TGF-β1            *In vitro*-HPASMCs                         ↓TGF-β1, ↓HPASMCs, ↓HIF-1α, ↓AhR                                                                                                                         [@B56]

  Berberine                            100 mg/kg                              Hypoxia           *In vivo*-rat/*In vitro*-PASMCs            ↓proliferation and migration of PASMCs, ↓RV/(lV + S), ↓Medial wall thickness, ↓PP2Ac                                                                     [@B84]

  Carvacrol                            *In vivo*: 100 mg/kg\                  Hypoxia           *In vivo*-rat/*In vitro*-PASMCs            ↓RV/LV+S, ↓MDA, ↑SOD, ↑GSH, ↓Bcl-2, ↓Procaspase-3,\                                                                                                      [@B165]
                                       *In vitro*: 600 μM                                                                                  ↑Caspase-3, Inhibit the ERK1/2 and PI3K/Akt pathway                                                                                                      

  Genistein                            1 mg/kg                                MCT               *In vivo*-rat/*In vitro*-HPASMC and NRVM   ↓RVP, ↑VEF, ↓RVEF, ↑ERβ\                                                                                                                                 [@B88]
                                                                                                                                           ↓HPASMCs, Improvements in cardiopulmonary function, ↓RHF                                                                                                 

  Ginsenoside Rb1                      *In vitro*: 10 μg                      Hypoxia and MCT   *In vivo*-rat/*In vitro* PASMCs            ↓ET-1, ↓SOCE, ↓RV(LV+S), ↑Relaxation                                                                                                                     [@B149]

  Isorhynchophyl line (IRN)            *In vivo*: food containing 0.1% IRN\   MCT               *In vivo*-rat/*In vitro*-PASMCs            ↓Cyclin D1, ↓CDK6, ↑p27Kip1, ↓ERK1/2, ↓STAT3, ↓Akt/GSK3β, ↓RVP, ↓RVH                                                                                     [@B45]
                                       *In vitro*: 25 μM                                                                                                                                                                                                                                            

  Luteolin                             5 mM/kg                                Hypoxia           *In vivo*-dog                              ↓PAP, ↓Aortic pressure                                                                                                                                   [@B101]

  Magnesium lithospermate B            *In vivo*: 15 mg/kg\                   Hypoxia           *In vivo*-rat/*In vitro*-PASMCs            ↓RVSP, ↓NOX2, ↓NOX4, ↓ERK, ↓ROS, ↓H~2~O~2~, ↓OPN, ↓Cyclin D1, ↑α-SMA, ↑SM22α                                                                             [@B78]
                                       *In vitro*: 20 μM                                                                                                                                                                                                                                            

  Nobiletin                            50 mg/kg                               MCT               *In vivo*-rat/*In vitro*-PASMCs            ↓RVSP, ↓RVH, ↓RV/(LV+S) ↓Src/STAT3, ↓PDGF-BB, ↓Src/STAT3                                                                                                 [@B22]

  Oxymatrine                           *In vivo*: 50 mg/kg\                   MCT and hypoxia   *In vivo-*rat*/In vitro-*PASMCs            ↓RVSP, ↓RV/\[LV+S\], ↓Cell number, ↓MCP-1, ↓IL-6, ↓SDF-1, ↓TGF-β, ↓VEGF, ↓ICAM-1, ↓VCAM-1, ↑SOD, ↑HO-1, ↑GSH, ↑Nrf2                                      [@B164]
                                       *In vitro*: 0.2 mg/mL                                                                                                                                                                                                                                        

  *Panax notoginseng* Saponins         50 mg/kg                               Hypoxia           *In vivo*-rat                              ↓PAP, ↓RV/(LV+S), ↓p-p38MAPK, ↓p38MAPK                                                                                                                   [@B166]

  Polydatin                            20 mg/kg                               Hypoxia           *In vivo*-rat                              ↓mPAP, ↓mCAP, ↓RVH, ↓Ang II, ↓ET, ↑NO                                                                                                                    [@B92]

  Punicalagin                          45 mg/kg                               Hypoxia           *In vivo*-rat                              ↓RVH, ↓mPAP, ↓RV/(LV+S), ↓MMP-9, ↓HIF-1α, ↓NF-kB, ↓TNF-α, ↓VEGFA, ↑SOD, ↑cGMP, ↑NO                                                                       [@B123]

  Quercetin                            *In vivo*: 100 mg/kg\                  Hypoxia           *In vivo*-rat/*In vitro*-PASMCs            ↓PAH, ↓RVH, ↓Cell migration, ↑cyclin D1, ↓cyclin B1, ↓Cdc2, ↓MMP2, ↓MMP9, ↓CXCR4, ↓Integrin β1, ↓integrin α5, ↓TrkA/AKT signaling pathway, ↑BAX, ↓BCL2   [@B48]
                                       *In vitro*: 60 μM                                                                                                                                                                                                                                            

  Quercetin                            100 mg/kg                              MCT               *In vivo*-rat/*In vitro*-PASMCs            ↓mPAP, ↓RVH, ↓PCNA, ↓WT                                                                                                                                  [@B41]

  Resveratrol                          100 μM/L                               Hypoxia           *In vitro*-PASMCs                          Inhibiting the PI3K/AKT signaling pathway, ↓p-Akt, ↓MMP-2 and MMP-9                                                                                      [@B44]

  Resveratrol                          *In vivo*: 40mg/kg\                    Hypoxia           *In vivo*-rat/*In vitro* PASMCs            ↓RVSP, ↓HIF-1α, ↓ROS, ↓PH, ↓IL-6, ↓IL-1β, ↓TNF-α, ↓NF-κB\                                                                                                [@B158]
                                       In vitro: 40 μM                                                                                     ↑Trx-1, ↑ Nrf-2                                                                                                                                          

  Resveratrol and Trimethoxystilbene   Resveratrol: 200 μM\                   TNF-α             *In vitro*-PASMCs                          ↓PASMCs, TMS was more potent compared with RES                                                                                                           [@B40]
                                       Trimethoxystilbene: 20 μM                                                                                                                                                                                                                                    

  Rhoifolin                            5 mM/kg                                Hypoxia           *In vivo*-dog                              ↓Cardiac output, ↓Aortic pressure                                                                                                                        [@B101]

  Salidroside                          *In vivo*: 32 mg/kg\                   Hypoxia           *In vivo*-rat/*In vitro* PASMCs            ↓RVH, ↓BCl2, ↑Caspase-3, ↑BAX, ↑A~2a~R                                                                                                                   [@B57]
                                       *In vitro*: 800 μM/L                                                                                                                                                                                                                                         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Results {#s3}
=======

Study Selection and Characteristics {#s3_1}
-----------------------------------

From 1290 studies, 172 studies were separated because of duplication; 395 studies were separated because they were reviews; 593 studies were separated based on their title and abstract; 82 studies were separated because they had not full text in English. From 48 remaining reports, 4 studies were separated because they were mixture of herbs and chemical compounds in the form of capsule; 2 studies were separated because they were induced PH and 1 study was separated because it was for fungus species (not plant). [**Figure 1**](#f1){ref-type="fig"} shows the method of the study and criteria for article separation. The general information of the articles were summarized in [**Table 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}.

![Study design and extraction.](fphar-11-00145-g001){#f1}

### Medicinal Plants used for PH Treatment {#s3_1_1}

#### Allium sativum *L.* {#s3_1_1_1}

*Allium sativum* L. (Garlic) is a herbal remedy used in traditional medicine for treatment of a wide range of diseases. The main constituents of *A. sativum* that are responsible for its medicinal actions are sulfur-containing compounds including crysteine sulfoxides. Alliin is part of this group, which could be transformed into thiosulfinates ([@B116]; [@B51]).

Some of the therapeutic actions of *A. sativum* such as lowering blood glucose levels, reducing oxidative stress, anticancer, reducing inflammation, immune system enhancer, anti-infectious diseases and cardiovascular protective were demonstrated ([@B73]). There is evidence suggesting that *A. sativum* could relax vascular smooth muscles, to increase the activity of eNOS, and to hyperpolarize the smooth muscle cell membrane. [@B34] demonstrated that aqueous extract of *A. sativum* powder could prevent the progression of PH induced by hypoxia in rats due to its vasorelaxant activity.

#### Allium macrostemon *Bunge* {#s3_1_1_2}

*Allium macrostemon* Bunge is a member of Amaryllidaceae family and used in traditional Chinese medicine with many pharmacological activities: antitumor, antioxidant, antiasthmatic (due to its ability to relax the bronchial smooth muscle, reducing blood perfusion and the mean PAs pressure), enhancing immune system ([@B137]). Dimethyl disulfide (DMDS) is the main constituent of *A. macrostemon* (34.93%) that possesses many biological activities such as regulation of melanin formation, anti-inflammatory and anti-hypertensive, and therefore it is used for treatment of myocardial ischemia ([@B24]).

The study of [@B47] demonstrated that use of volatile oil of *A. macrostemon* in PAECs causes increase eNOS expression and serine 1177 phosphorylation. Serine 1177 is a residue for phosphorylation of eNOS in PKA, Akt, and Calmodulin processes ([@B36]). Also, volatile oil of *A. macrostemon* induces relaxation in PAs by activation of intracellular Ca^2+^/PKA/eNOS signaling pathway. Therefore, volatile oil of *A. macrostemon* and its active compound DMDS can improve PH by activation Ca^2+^/PKA/eNOS signaling pathway in PAECs ([@B47]).

#### Allium ursinum *L.* {#s3_1_1_3}

*Allium ursinum* L. (Wild garlic or bear\'s garlic), a member of Amaryllidaceae family, is a native plant of Eurasia. It is widely used in traditional medicine ([@B131]). *A. ursinum* produce a variety of chemical structures responsible for its biological activities. One of the main compounds are flavonoid glycosides and sulfur constituents responsible for its garlic-like fragrance. Some of the *A. ursinum* compounds like galactolipids and phytosterols are species-specific ([@B104]). Some of the most important pharmacological activities of *A. ursinum* are antiaggregatory effects on human platelets, inhibition effect on 5-lipoxygenase (5-LOX) and prostaglandin-endoperoxide synthase (PTGS) enzymes *in vitro*, high antioxidant activity and inhibition of *in vitro* cholesterol biosynthesis. Its action is also associated with a decrease in blood pressure and phosphodiesterase enzyme (PDE 5A) inhibition. The saponins and flavonoids found in *A. ursinum* could inhibit PDE5A activity ([@B79]). Upregulation of PDE5 has been reported in PH ([@B68]). The treatment of pulmonary hypertensive rats with *A. ursinum* reverses RVH and the pulmonary vascular remodeling evaluated through the increasing of RV/(LV+S) ratio and the pulmonary arterial wall thickness respectively compared to untreated pulmonary hypertensive rats ([@B15]).

#### Crataegus rhipidophylla *Gand.* {#s3_1_1_4}

*Crataegus rhipidophylla* Gand. (syn. *Crataegus oxyacantha* L.; Hawthorn) is a member of Rosaceae family and it is native to Europe, Africa and Asia ([@B18]). Some of the bioactive compounds found in *C. rhipidophylla* (fruits, leaves, and flowers) are epicatechin, hyperoside, and chlorogenic acid. Its extracts have many pharmacological activities such as neuroprotective, hepatoprotective, cardioprotective, nephroprotective ([@B121]).

Flavonoid extracts of *C. rhipidophylla* cause improvement in body weight gain, reduction of heterophil to lymphocyte ratio and an increase of NO levels on PH induced by high altitude in broiler chickens ([@B4]). Treatment of broiler chickens with these extracts could overexpress the iNOS and SOD-1, and reduce the expression of ET-1 in the heart tissue.

Polyphenols (mainly flavonoids) and oligometric proanthocyanidins (OPCs) compounds of *C. rhipidophylla* are responsible for some of these activities, such as antioxidant, anti-anxiety, anti-cancer and growth inducer. ([@B135]).

Treatment with *C. rhipidophylla* extract mix in drinking water of broiler chickens with pulmonary hypertension syndrome (PHS) induced by high altitude suggested that the extract cause an increase in albumin, globulin, food intake and body weight and a decrease in AST, ALT, ALP, and RV : TV ratio ([@B3]). ALP is one of the serum\'s enzymes which is a marker of liver tissue damage and the two liver enzymes, AST and ALT, increase their concentrations in oxidative stress conditions and hypoxic state before PHS. These liver enzymes are sensitive markers for measuring oxidative stress, which is an important factor during PHS progression ([@B35]). Therefore, the decrease in ALP, ALT and AST levels show reduction of tissue damage due to oxidative stress and that could lead to inhibition of PHS progression ([@B3]).

#### Eulophia macrobulbon *(E.C.Parish & Rchb.f.) Hook.f.* {#s3_1_1_5}

*Eulophia macrobulbon* (E.C. Parish & Rchb. f.) Hook.f. (Corduroy orchid) is a member of Orchidaceae family. Orchids are commonly used in traditional medicine in Asia, Europe and America. Their pharmacological activities include the treatment of pulmonary, autoimmune and inflammatory diseases, cancer, and diabetes ([@B99]). The ethanolic extract of *E. macrobulbon* contains flavonoids, terpenoids and phosphodiesterase type 5 (PDE5) inhibitor, so it could be a pulmonary vasodilator ([@B138]).

[@B154] during a study on MCT induced PH in rats, demonstrated that the treatment with ethanolic extract of *E. macrobulbon* inhibits CaCl~2~-induced contraction in PA rings *in vitro* and reduces (RV/LV+S) ratio. Stilbenes and their derivatives found in *E. macrobulbon* extracts are responsible for inducing relaxation in coronary arteries in hypercholesterolemic pigs ([@B142]). Therefore, it has been suggested that *E. macrobulbon* extract could induce relaxation in PAs (like coronary arteries) and modulate PH ([@B154]).

#### Kelussia odoratissima *Mozzaf* {#s3_1_1_6}

*Kelussia odoratissima* Mozzaf. (Wild celery) is a member of Umbelliferae family, that grows at high altitudes (more than 2000 m a.s.l.), mainly in Iran. It is commonly used in Iranian traditional medicine for hypertension and inflammation treatments. Active compounds of its essential oil are phthalides, (*Z*)-ligustilide and terpenes ([@B126]). The alcoholic extract includes components with high antioxidant activity such as flavonoids and polyphenols ([@B111]).

Results of the study of [@B2] on broiler chickens with PH shows improvement in body weight gain, an increase in NO levels and heterophil/lymphocyte ratio and a decrease in MDA levels in serum. In the broiler chickens overexpression of SOD1 and iNOS and suppression of the expression of ET-1 gene in the heart tissue were observed due to treatment with *K. odoratissima*. Thus, this herb could improve the outcomes of PH in broiler chickens.

#### Mimosa pigra *L.* {#s3_1_1_7}

*Mimosa pigra* L. (giant sensitive tree) is a member of Fabaceae family, popular with its therapeutic application in the countries of Africa, America and Asia. It is used for treatment of many diseases such as cardiovascular diseases, digestive disorders and infections ([@B119]).

[@B115] in a study on therapeutic potential of *M. pigra* against hypoxia-induced PH in rats, indicated that this plant can increase NO production, reduce PAP and RV/(LV+S) and p38 MAPK expression and phosphorylation in lung tissue. P38 MAPK activated in pulmonary hypertensive rats ([@B153]). The results of these studies suggested that *M. pigra* has ameliorative effect on PH outcomes.

#### Moringa oleifera *Lam.* {#s3_1_1_8}

*Moringa oleifera* Lam. (Drumstick tree) belongs to the Moringaceae family and it is widely cultivated in tropical and subtropical areas. It is native to Northwestern India. Some therapeutic applications of the herb are associated with a decrease in blood pressure, reduction of cholesterol levels, with its high antioxidant, hypoglycemic, anti-ulcer and anticancer activities ([@B134]). Nitryl glycosides compounds of *M. oleifera* leaves show hypotensive and antioxidant activities ([@B46]). Other studies show that *M. oleifera* can increase the GSH levels in liver tissue ([@B33]).

[@B20] found an increase in SOD levels and a decrease in pulmonary pressure and in pulmonary arterial wall thickness due to treatment with *M. oleifera* in MCT induced PH in rats. It has been demonstrated that niazirin and thiocarbamates (two of the active compounds of *M. oleifera*) have antihypertensive effects on spontaneous hypertension in rats ([@B32]). So it could be considered as an useful treatment for PH.

#### Rhodiola tangutica *(Maxim.) S.H.Fu* {#s3_1_1_9}

*Rhodiola tangutica* (Maxim.) S.H.Fu (syn. *Sedum algidum* var. *tanguticum* Maxim.) (Rhodiola, Golden root) is an important herb used in traditional medicine in Qinghai and Tibetan. It is used for treatment of many diseases especially to prevent colds caused by high altitude ([@B75]). Some of the biologically active substances of enrich fraction of *R. tangutica* are phenylethanols, flavonoids, terpenoids ([@B98]).

[@B98] during a study on hypoxia-induced PH in rats marked that the use of bioactive enriched fraction of *R. tangutica* can decrease mPAP, RV/BW, RV/LV+S, hematocrit and p27Kip1 protein expression and therefore could increase protein expression of PCNA, CDK4, and Cyclin D. These three proteins have key roles in cell cycle switching of G0/G1 phase to S phase. P27kip1 is a CDK inhibitor. Therefore, regulation of these factors can inhibit cell proliferation and following that could inhibit medial vessel thickness, which is a factor for structural changes in pulmonary hypertension.

Vasorelaxant activity of *R. tangutica* was confirmed by *in vitro* study on isometric tension changes induced by a force transducer in rat pulmonary artery ([@B77]). Therefore, according to these studies *R. tangutica* could be considered as an effective treatment for PH.

#### Salvia miltiorrhiza *Bunge* {#s3_1_1_10}

*Salvia miltiorrhiza* Bunge (Red sage, Danshen) is a member of Lamiaceae family and it is highly valued for its roots. In traditional Chinese medicine, it is used to increase blood flow and cooling the blood in abscess treatment. The main chemicals of aqueous extract of *S. miltiorrhiza* are caffeic acid metabolites ([@B83]; [@B151]). Some of the pharmacological activities of *S. miltiorrhiza* in traditional medicine are protection of myocardium derangement induced by ischemia, protection of neural cells injuries induced by anoxia, inhibition of the platelet aggregation, hepatic fibrosis and HIV-1 ([@B74]). Also, this plant is used as a protective agent on vascular endothelial cells ([@B151]). It has protective effect on disorders that contributed to endothelial dysfunction or vascular endothelial injury, like focal cerebral infarction and cerebral ischemia ([@B17]).

[@B147] suggested that treatment of pulmonary hypertensive rats with *S. miltiorrhiza* aqueous extract could improve hemodynamic parameters such as mPAP and RVSP. It also increased NO and 6-Keto-PGF1*α* and decreased ET-1 and TXB2 levels in the plasma and down-regulated the expression of TGF-β1 in lung tissue which is one of the important factors in inducing vascular remodeling and consequently, PH progression. Endothelial injury causes imbalance of vasoactive substances such as vasorelaxant (PGI2 and NO), and vasoconstrictors (ET-1 and TXA2). These results suggest that *S. miltiorrhiza* can be considered as a treatment for PH by increasing NO levels and decreasing ET-1, TXA2, and TGF-β1 expression in lung tissue and improvement of hemodynamic indices.

[@B127] in a study on hypoxia induced pulmonary hypertensive rats suggested that *S. miltiorrhiza* can be an effective treatment for PH due to its reducing activity on RVSP and RVHI. [@B19] demonstrated that *S. miltiorrhiza* in pulmonary hypertensive rats could reduce thickening in the SPAs, could increase the levels of HO-1 and iNOS and decrease the expression of eNOS. In high altitude conditions, HO-CO pathway is up-regulated and the expression of HO-1 protein and the CO production increased. In other words, HO-CO is a pathway related to pulmonary arterial vasodilation and protective from pathological remodeling ([@B81]). Therefore, according to the available evidence, *S. miltiorrhiza* could ameliorate PH.

#### Securigera securidaca *(L.) Degen & Dörfl*. {#s3_1_1_11}

*Securigera securidaca* (L.) Degen & Dörfl. (Goat pea), a member of Fabaceae family, that grows at West Asia, Europe and Africa. It is used in traditional medicine for treatment of many diseases such as chronic obesity, diabetes, central nervous system diseases, high blood pressure, and digestive problems ([@B52]). Flavonoids, alkaloids and saponins are found in its aqueous and alcoholic extracts ([@B1]). [@B5] reported that the treatment with *S. securidaca* in broiler chickens with PH could increase NO levels in plasma. NO is a vasorelaxant agent and can improve PH. The flavonoids found in *S. securidaca* could protect NO from inactivation by scavenging superoxide anions. The results of Ahmadipour\'s study show that the treatment with *S. securidaca* could improve hemodynamic parameters and can decrease R, S and T wave amplitudes of the electrocardiogram. This plant can reduce oxidative stress by reducing MDA levels. It has been suggested that the antioxidant properties of *S. securidaca* are due to phytosterols, 4‐Methyl‐2,6‐di‐tertbutylphenol, palmitic acid, 9,12-octadecadienoic acid and alkaloidal compounds. Therefore, these compounds could be considered as an appropriate treatment for PH ([@B5]). Several studies demonstrated that there is a strong relationship between ET-1 expression and PH. ET-1 expression in PH broilers chicken increased compared with normal broilers ([@B37]). Studies show that *S. securidaca* can reduce ET-1 expression in high altitude-induced PH in broiler chicken ([@B5]). Also, flavonoids found in *S. securidaca* can reduce transmembrane 45Ca^2+^ absorption or inhibit protein kinase C activity, inhibit cAMP‐ and cGMP-phosphodiesterase (PDE) ([@B13]) and that eventually leads to reduction in contraction of the vascular system and PH improvement. Therefore, *S. securidaca* with its vasorelaxant and antioxidant activities can ameliorate outcomes of PH ([@B5]).

#### Terminalia arjuna *(Roxb. ex DC.) Wight & Arn.* {#s3_1_1_12}

*Terminalia arjuna* (Roxb. ex DC.) Wight & Arn. (Arjuna) is an evergreen tree grow in India, a member of the Combretaceae family. It is used in traditional medicine to improve cardiovascular disease ([@B30]). Some of the active compounds of *T. arjuna* include flavonoids, terpenoids, tannins and minerals ([@B141]). Some of the pharmacological activities of *T. arjuna* are anti-ischemic, antioxidant, hypolipidemi, increasing cardiac contraction and decreasing blood pressure, ([@B108]; [@B67]).

[@B90] found that the aqueous extract of *T. arjuna* stem bark can prevent the decrease of relative weight of lungs in pulmonary hypertensive rats. The study was performed on MCT-induced PH rats. The effects of *T. arjuna* are associated also with reduction of RV hypertrophy and %MWT of pulmonary artery, with decrease lipid peroxidation and NOX1 protein expression in lung and with increase the SOD and CAT, also with decrease in BCL2/BAX ratio mRNA demonstrating antiapoptotic effect of the *T. arjuna* in pulmonary hypertensive rats. The results of these studies suggest that *T. arjuna* can be considered as an effective treatment for PH.

#### Trifolium pratense *L.* {#s3_1_1_13}

*Trifolium pratense* L. (Red clover) belongs to Fabaceae family. It is native to Europe, West Asia and Northwest Africa. Several types of flavonoids are essential constituents of *T. pratense* ([@B16]). A study on animal models suggested that isoflavones in *T. pratense* can reduce contractions of the smooth muscle in ileum, uterus and bladder ([@B145]). [@B63] demonstrated that the use of isoflavones of *T. pratense* extract, mixed in food, in broiler chickens with PH could reduce ET-1 in serum and lungs and could increase the secretion of NOS. ET-1 can increase the MMP-2 expression that is related to pulmonary vascular remodeling ([@B137]). *T. pratense* has phytoestrogen activity and can increase NOS and NO levels in the serum ([@B128]). All of these findings suggested that *T. pratense* isoflavones have therapeutic potential for PH in bird models by increasing in NO and decreasing in ET-1 expression.

#### Withania somnifera *(L.) Dunal* {#s3_1_1_14}

*Withania somnifera* (L.) Dunal (Ashwagandha) is a herbal remedy belongs to Solanaceae family which is used for treatment of many diseases especially in India ([@B93]). HPLC analysis shows withaferin A and withanolide A as the most important active components of *W. somnifera* root powder extract ([@B69]). Pharmacological uses of *W. somnifera* include anti-fatigue, bone enhancer, anti-aging, anti-Alzheimer, anti-inflammatory, antioxidant, hypoglycemic and anticancer ([@B103]). It is used also to lower blood pressure and to lower cholesterol levels in the blood ([@B94]).

[@B69] during a study on MCT induced pulmonary hypertensive rats shows that the treatment with *W. somnifera* can reduce RVP and RVH, also could reduce the expression of PCNA. The treatment with *W. somnifera* causes an increase in procaspase-3 expression, and therefore inducement of apoptosis in pulmonary vessels. In addition, treatment with *W. somnifera* could reduce ROS levels in lung tissue. It can increase the levels of IL-10 and decrease in levels of TNF-α and NFkB, which is in connection with its anti-inflammatory effect. Withanolides found that *W. somnifera* inhibit the activation of NFkB by inhibition of TNF-α and show the anti-inflammatory effect of *W. somnifera* ([@B61]). *W. somnifera* also increases eNOS expression and decreases HIF-1α expression in lung tissue (HIF-1α increases in hypoxia conditions). Increased eNOS activity can increase NO levels, which cause vasorelaxation ([@B69]). According to the mentioned studies, *W. somnifera* could be a potential herb in the treatment of PH by its antioxidant, vasorelaxant and anti-inflammatory activities.

### Phytochemicals Used for PH Treatment {#s3_1_2}

#### Apple Polyphenol {#s3_1_2_1}

Apple polyphenol is a compound that derived from different types of apple fruits (*Malus* spp.), with many pharmacological activities for treatment of diseases such as gastric mucosal damage, cancers, inflammatory and cardiovascular diseases ([@B31]).

[@B55] during a study on hypoxia-induced PH in rats found that treatment with apple polyphenol can modulate hemodynamic indicators such as mPAP and PVR and therefore could decrease the contraction of pulmonary vessel rings. *In vitro* it decreases cytosolic Ca^2+^ in PASMCs. At the genetic level, apple polyphenol causes an increase of eNOS expression, an increase of NO levels and decrease in caspase-3 and iNOS expression in PAEC. Therefore, all of these findings confirm that apple polyphenol can be considered as a treatment for PH that induces its effect by reducing of contraction and increasing of NO levels.

#### Asiaticoside {#s3_1_2_2}

Asiaticoside is a saponin derived from *Centella asiatica* (L.) Urb. and it has many applications in traditional medicine with high range of biological activities such as antioxidant, anti-inflammatory, anti-hepatofibrotic ([@B27]) and neuroprotection effect on transient cerebral ischemia and reperfusion ([@B21]).

[@B150] during a study on hypoxia induced PH shows that treatment with asiaticoside decreased the RVH and mPAP, also increase the concentration of cGMP and NO and decrease circulating concentration of ET-1. Additionally, this compound increase the activity of AKT, the phosphorylation and therefore leads to activation of eNOS and to inhibition of endothelial cells apoptosis. Studies suggested that asiaticoside can enhance phosphorylation and activation of serine/threonine-proteinn kinase/eNOS pathway and therefore to increase NO production that inhibits the progression of PH.

[@B148] during an *in vivo* and *in vitro* investigation on hypoxia induced PH in rats and PASMCs demonstrated that treatment with asiaticoside improves the mPAP and RVH, also reduces the expression of TGF-β1, TGF-βR1, and TGF-βR2 and inhibits the phosphorylation of Smad2/3 in lung tissue of animals. It has been shown that Smad2/3 phosphorylation raises during PH progression ([@B118]). In PASMCs asiaticoside reduces the cell number and migration, also reduces the TGF-β1 expression. So asiaticoside do its therapeutic effect by reducing proliferation and raising apoptosis ([@B148]).

#### Astragalus Polysaccharides {#s3_1_2_3}

*Astragalus* polysaccharides are active compounds derived from *Astragalus membranaceus* Fisch. ex Bunge, that have many pharmacological activities especially anti-inflammatory and antioxidant ([@B7]).

[@B163] during a study on MCT induced PH in rats demonstrated that treatment with *Astragalus* polysaccharides causes improvement in hemodynamic indicators such as decreasing mPAP, PVR, RVH and medial wall thickness. In addition, overexpression of eNOS and increase of NO levels were observed in treatment groups. Decrease in pro-inflammatory mediators levels were observed due to treatment with *Astragalus* polysaccharides. Also, decrease in the expression of pho-IκBα was confirmed. Pho-IκBα is a marker for assessment of inflammation, so according to the studies *Astragalus* polysaccharides can be a useful treatment for PH by inhibition of the inflammation and by increasing of NO levels leading to improvement of hemodynamic indicators.

#### Baicalin {#s3_1_2_4}

Baicalin is a flavonoid derived from *Scutellaria baicalensis* Georgi roots and it is used in traditional medicine with many pharmacological activities such as antioxidant, anticancer, anti-inflammatory and inducing apoptosis ([@B28]). Studies show that baicalin could inhibit the expression of collagen I due to its anti-fibrotic activity ([@B54]). [@B146] demonstrated that pulmonary arterial collagen is an important factor in PH due to hypoxic conditions.

[@B80] during a study on hypoxia-induced PH shows that treatment with baicalin cause improvement of hemodynamic factors including mPAP, mSAP, and RV/(LV+S)%. Also, baicalin reduces protein and mRNA expression of collagen I in lung tissue, which is an index for PH progression. It should be noted that baicalin has small effect on collagen III protein and mRNA expression compared with its great effect on collagen I mRNA and protein expression. Baicalin increases the expression of ADAMTS1 and therefore inhibits the expression of collagen I. Therefore, baicain can be considered as a treatment for PH due to its inhibitory effect on collagen I synthesis and improvement in hemodynamic factors ([@B80]).

[@B56], during a study on HPASMCs exposed to TGF-β1, demonstrated that treatment with baicalin decrease the expression of HIF-1α and AhR that are responsible for cell proliferation. So treatment with baicalin, *in vitro*, cause decrease of proliferation and it can be considered for improving the conditions caused by PH. Studied prove that treatment with baicalin can improve PH by anti-proliferation effect mediated by the AhR pathway.

[@B53] during a study on MCT induced PH in rats shows that treatment with baicalin causes improvement of hemodynamic indicators such as RVSP and RVH, also reduction of ET-1 and ETA (ETAR) protein receptor expression in lungs and therefore leads to suppression of the Akt/ERK1/2/GSK3β/β catenin signaling pathway. Activation of this pathway cause increase of the ET-1 expression and progression of PH. Additionally, the reduction of superoxide production and increase the expression of eNOS were observed in treated rats. It has been demonstrated that the treatment with baicalin causes decrease of von Willebrand factor (vWF), which is a marker of endothelial injury ([@B53]). These results suggest that baicalin can be considered as a potent treatment for PH.

#### Berberine {#s3_1_2_5}

Berberine is an isoquinoline alkaloid derived from some Chinese herbs, such as *Coptidis* rhizome ([@B168]). It has many pharmacological activities: antimicrobial, antiproliferative, cardioprotective, antidiabetic, anticancer and others ([@B42]; [@B100]; [@B10]).

[@B84] during a study shows that treatment with berberine cause decrease of protein phosphatase 2A (PP2Ac) phosphorylation, which has an important role in the progression of PH. Therefore the decrease of PP2Ac expression cause decrease in the proliferation and migration of PASMCs which leads to improvement of PH; also treatment with berberine leads to improvement in hemodynamic indicators such as RV/(LV + S) and to reduction of medial wall thickness percentage.

#### Carvacrol {#s3_1_2_6}

Carvacrol is a monoterpenoid phenol, derived from oregano (*Origanum* spp.) and thyme (*Thymus* spp.) leaves. Some of the most important pharmacological activities of carvacrol are antibacterial, antiviral, antioxidant and anticancer ([@B120]).

[@B165] during a study on hypoxia-induced PH in rats demonstrated that carvacrol reduces RVH and the thickening of pulmonary arteries. Also, it can reduce oxidative stress by increasing SOD and GSH activity and decreasing MDA levels in PASMCs. Treatment with carvacrol reduces the levels of mRNA and protein expression of Bcl-2 (anti-apoptotic protein) and reduces the Procaspase-3 expression, raises the caspase-3 expression and so it can increase PASMCs apoptosis. Also, ERK1/2 and Akt increase cell survival and decrease apoptosis. Additionally, carvacrol treatment inhibits the ERK1/2 and PI3K/Akt pathway. All of these findings demonstrate that carvacrol can ameliorate PH by increasing apoptosis and decreasing oxidative stress in PASMCs.

#### Genistein {#s3_1_2_7}

Genistein is a phytoestrogen which has higher affinity to ERβ compared with ERα. This natural compound has many pharmacological activities such as vasodilator, cardioprotective, and anti-inflammatory. It has been suggested that genistein has protective effect on PH progression ([@B50]).

[@B88] during a study on MCT induced PH shows that treatment with genistein can improve hemodynamic indicators including RVP, RVH, RVEF, and RV dilatation. Genistein also decreases pulmonary fibrosis and tissue injuries due to PH. Genistein causes increase in protein expression of ERβ in lung and RV. *In vitro* studies show that genistein inhibits the proliferation of HPASMCs and hypertrophy of NRVM.

All of the protective effects of genistein on PH are related to its phytoestrogenic activity. Various studies have shown that estrogens have protective effects against cardiovascular and PH disease and this effect is *via* estrogen receptor-β (ERβ) ([@B140]). Therefore, genistein as a phytoestrogen, can modulate PH outcomes by affecting on ERβ expression.

#### Ginsenoside Rb1 {#s3_1_2_8}

Ginsenoside Rb1 is one of the phytochemicals derived from *Panax ginseng* that shows many pharmacological activities especially in the treatment of heart and lung diseases like treatment of endothelial injuries and inflammation disorders in endothelial smooth muscle cells ([@B162]; [@B76]).

[@B149] during an investigation on hypoxia and MCT induced PH in rats demonstrated that treatment with Ginsenoside Rb1 improves PH *in vivo* and *in vitro* by improving RV/(LV+S) ratio, reducing the expression of ET-1 and SOCE and induces relaxation in PAs. The concentration of cytosolic Ca^2+^ adjusted by SOCE in PASMCs and it\'s a key factor for contraction and proliferation of PASMCs. Ginsenoside Rb1 do its therapeutic effect by reducing the ET-1 and SOCE expression and reducing contraction, so it can be considered as a treatment for PH.

#### Isorhynchophylline {#s3_1_2_9}

Isorhynchophylline is an alkaloid derived from *Uncaria rhynchophylla* (Miq.) Miq. ex Havil. and it is widely used in traditional medicine especially for treatment of heart and brain diseases ([@B167]). Some of the pharmacological activities of isorhynchophylline include reducing oxidative stress, apoptosis, anticancer and anti-inflammatory ([@B70]).

[@B45] during a study on MCT induced PH in rats shows that treatment with isorhynchophylline can improve RVP and RVH. Also, isorhynchophylline can reduce PASMCs proliferation *in vitro*. They also demonstrated that isorhynchophylline can reduce the expression of Cyclin D1 and CDK6, and can increase the expression of p27Kip1 and therefore it can regulate cell cycle and could reduce proliferation. Isorhynchophylline inhibits ERK1/2 and STAT3 signaling pathways and this way it can suppress cell growth ([@B45]). All of these findings suggested that isorhynchophylline can be considered as a potent treatment for PH that causes regulation of cell cycle and inhibit cell growth and proliferation.

#### Magnesium lithospermate B {#s3_1_2_10}

Magnesium lithospermate B is a phytochemical isolated from *Salvia miltiorrhiza*. Studies shows that magnesium lithospermate B is a potent antioxidant that do its effect through inhibition of NADPH oxidase; NADPH oxidase (NOX) is a factor contributing to increased ROS and cell damage ([@B82]; [@B64]).

[@B78] during an *in vivo* and *in vitro* investigation shows that treatment of pulmonary hypertensive rats and PASMCs with magnesium lithospermate B reduces the expression of NOX2 and NOX4 and ERK in PAs, also reduces the ROS and H~2~O~2~ levels. In PASMCs, it reduces OPN and Cyclin D1 and raises α-SMA and SM22α expression (contractile genes with high and low rate of proliferation, respectively). So, based on these findings magnesium lithospermate B can be considered as a potent treatment of PH by modulating oxidative stress in PAs of animals and modulating contractile genes in PASMCs.

#### Nobiletin {#s3_1_2_11}

Nobiletin is a flavonoid derived from peels of citrus fruits. This compound has many applications due to its biological activities such as anti-inflammatory, antioxidant and anti-tumor ([@B58]).

[@B22] during a study on MCT induced pulmonary hypertensive rats suggested that treatment with nobiletin leads to improvement of hemodynamic indicators such as RVSP and RVH and therefore has a positive effect on pulmonary vascular remodeling induced by hypoxia. In *in vitro* conditions, nobiletin suppresses PDGF-BB, Src and STAT3 phosphorylation, after that it suppresses Pim1 and NFATc2, which are target genes of Src and STAT3. Finally, this gene cascade inhibits proliferation. Therefore, nobiletin can prevent the progression of PH by its inhibition effect on Src/STAT3 axis that is one of the pathways of proliferation.

#### Oxymatrine {#s3_1_2_12}

Oxymatrine is a phytochemical found in *Sophora flavescens* Ait. that shows many pharmacological activities such as anti-inflammatory and antioxidant activities especially in lung and heart tissues, compared to other organs ([@B66]); studies shows its protective effect against lung injury ([@B156]).

[@B164] during an investigation on hypoxia and MCT induced PH in rats (*in vivo*) and PASMCs (*in vitro*) shows that it cause improvement of PH by reducing the mRNA expression of inflammatory factors, chemokines and cytokines, growth and adhesion factors including MCP-1, IL-6, SDF-1, TGF-β, VEGF, ICAM-1, and VCAM-1. It also improves hemodynamic indicators. In addition, oxymatrine decreases the expression of HIF-1α and p-NF-κB in lung tissue and increased antioxidant factors including Nrf2, SOD, Ho-1 and GSH in PASMCs. This phytochemical can modulate PH *in vitro* and *in vivo* and in both hypoxia and MCT models by its antioxidant, antiproliferative and antiinflammatory effects.

#### Panax notoginseng *Saponins* {#s3_1_2_13}

*Panax notoginseng* Saponins (PNS) are compounds that are used in traditional Chinese medicine due to their biological and therapeutic activities such as vasorelaxant, antioxidant and inhibitory effect on vascular smooth muscle receptor of the voltage-gated Ca^2+^ channels ([@B23]).

[@B166] during a study on PNS injection on pulmonary hypertensive rats induced by hypoxia, shows that PNS can improve hemodynamic indicators such as mPAP, mCAP and RV/(LV+S) ratio and therefore can reduce the expression of p38MAPK mRNA in lung tissue of pulmonary hypertensive rats. P38MAPK is an important index for physiological stress and its expression increases during PH progression. So according to the studies, PNS could be considered as a treatment for PH.

#### Polydatin {#s3_1_2_14}

Polydatin is a phytochemical derived from *Polygonum cuspidatum* and has many pharmacological and therapeutic activities such as antiinflammatory, antioxidant, anticancer and inhibition of platelet aggregation ([@B91]).

Studies shows that during the progression of PH, increase in the levels of endothelin and angiotensin II leads to reduce in the bioavailability of NO ([@B14]). [@B92] during an investigation on hypoxia induced PH in rats showed that treatment with polydatin increases the NO levels *via* reduction of endothelin and angiotensin II levels in lung and serum. It also cause improvement of hemodynamic indicators like mPAP, mCAP and RVH.

#### Punicalagin {#s3_1_2_15}

Punicalagin is a phytochemical isolated from pomegranate juice and has many pharmacological activities due to its high antioxidant content ([@B157]); also it has been reported that punicalagin used for treatment of lung diseases in animal models ([@B109]).

[@B123] during an investigation on hypoxia induced PH in rats shows that treatment with punicalagin improves hemodynamic indicators and induce relaxation by enhancing NO-cGMP signaling pathway in PAs. Also this phytochemical reduces oxidative stress and raises mRNA expression of MMP-9, HIF-1α, VEGFA, NF-kB and TNF-α in lung tissue of animals. All of these factors increase in hypoxia conditions and as mentioned, they returned to their normal level by punicalagin treatment. So this phytochemical can be considered as an effective treatment for PH.

#### Quercetin {#s3_1_2_16}

Quercetin is a flavonoid found in a wide range of plants and fruits with many biological activities such as antioxidant, anti-inflammatory, antitumor, antiproliferative, inducing apoptosis, antimetastatic, vasodilator and decreasing blood pressure ([@B96]). Also, it has been suggested that quercetin inhibits the progression of PH in rats ([@B95]).

[@B48] during a study on hypoxia induced PH in rats demonstrated that treatment with quercetin improves hemodynamic indicators such as PAH and RVH. Quercetin can inhibit the proliferation of PASMCs and can induce apoptosis in cells by inhibiting the TrkA/AKT signaling pathway. It was confirmed that quercetin increases the BAX expression and decreases the expression of Bcl-2. Additionally, quercetin causes an increase of cyclin D1 and a decrease of cyclin B1 and Cdc2 protein expression. They are responsible for cell cycle regulation and reduce the expression of MMP2, MMP9, CXCR4, integrin β1 and integrin α5 which are responsible for cell migration. [@B41] during an investigation on MCT induced pulmonary hypertensive rats demonstrated that treatment with quercetin reduces the proliferation in PASMCs *via* reducing the expression of PCNA gene also quercetin reduces mPAP and RVH and WT in treated rats. So they shows that quercetin do its therapeutic effect by inhibition of proliferation in PASMCs. Therefore, quercetin can be considered as a treatment for PH by its prevention effect on migration and by its apoptosis inducing effect.

#### Resveratrol {#s3_1_2_17}

Resveratrol is a powerful antioxidant with a polyphenolic structure. It has many biological activities and therefore has many therapeutic applications such as antiinflammatory, antioxidant and antiaging ([@B62]; [@B161]). The anticancer activity of resveratrol is due to its inhibition of ACT, which leads to increase of apoptosis in human uterine cancer cells ([@B139]).

[@B44] during a study on pulmonary artery vascular smooth muscle cells (PASMCs) which have been exposed to hypoxia, demonstrated that treatment with resveratrol could inhibit proliferation and migration of PASMCs and after that could reduce AKT and p-AKT expression in PAMSCs. Also, resveratrol decreases the expression of MMP-2 and MMP-9. MMPs are responsible for increased migration and proliferation of PASMCs by activating the PI3K/AKT signaling pathway ([@B125]).

It has been suggested that resveratrol can increase the expression of *NO*, decrease inflammation, cell proliferation and oxidative stress. Therefore, it could improve the function of pulmonary artery endothelium and PH. Additionally, resveratrol can inhibit dysfunctions of rat pulmonary artery vessels (like inflammation and contraction that leads to PAH) and cardiomyocyte hypertrophy ([@B105]).

[@B158] during a study on hypoxia-induced PH *in vivo* and *in vitro*, demonstrated that resveratrol could improve PH and could reduce inflammatory mediators in the lungs of rats. Also treatments with resveratrol cause decrease of H~2~O~2~ in rats lungs. HIF-1α is an important gene in PH progression, NO and ROS activate HIF-1α expression ([@B113]) and resveratrol decreases its expression by its antioxidant activity. Trx-1 and Nrf-2 proteins expression were increased by resveratrol. Nrf2 is an antioxidant marker that has balancing effects on antioxidant proteins like Trx-1. Resveratrol increases GSH and SOD activities, Trx-1 and Nrf-2 protein levels in PASMCs and it decreases the proliferation of PASMCs and ROS, H~2~O~2~ production and expression of HIF-1α. All of these markers shows that resveratrol is a powerful antioxidant ([@B158]).

Trimethoxystilbene (TMS) is a synthesized compound from methylation of resveratrol that has more activities and low toxicity compared with resveratrol ([@B86]). [@B40] during an *in vitro* study on PASMCs shows that TMS is more potent in treatment of PH compared to resveratrol, by increasing induction of apoptosis and decreasing cell proliferation. Therefore, it is suggested that resveratrol can be a potent treatment for PH due to its antioxidant and anti-proliferative activities.

#### Rhoifolin, Apiin and Luteolin {#s3_1_2_18}

Rhoifolin, apiin and luteolin are three types of flavonoids used in traditional medicine. Studies show that flavonoids are present in the majority of vegetables and plants. Some of the biological and pharmacological activities of these flavonoids are anti-inflammatory, antiallergic and spasmolytic ([@B38]). It has been suggested that luteolin, apiin and rhoifolin have inhibitory effects on slow fibers of the dog heart; also they can reduce aortic pressure and capillary pulmonary pressure in normal animals ([@B102]).

[@B101], during a study on hypoxia-induced PH in dogs, demonstrated that structural changes of flavonoids (luteolin, apiin and rhoifolin) cause significant changes in antihypertensive activity. They showed that rhoifolin reduces aortic pressure but has not effect on pulmonary vascular resistance while luteolin and apiin have antihypertensive properties.

#### Salidroside {#s3_1_2_19}

Salidroside is a phytochemical isolated from *Rhodiola rosea* L. that widely used for PH treatment and has many pharmacological applications such as antioxidant, anticancer, antiinflammation and immune system enhancer ([@B106]; [@B43]).

[@B57] during an investigation on pulmonary hypertensive mice demonstrated that treatment with salidroside reduces RVH in treated mice and raises Caspase-3, BAX, A~2a~R and reduces BCL2 expression in PASMCs. Adenosine A~2a~R has protective effect in PH progression and inhibits vascular remodeling process. So according to this study, salidroside can be considered as a cure for PH by regulating apoptosis pathway.

Discussion {#s4}
==========

PH is a progressive disease characterized by increase in pulmonary blood pressure, right ventricular hypertrophy and thickening of the vascular intima, media, and adventitia ([@B143]). Vascular thickening is due to increased proliferation and resistant to apoptosis in PASMCs ([@B158]). Many signaling pathways are responsible in this regard such as Ca^2+^ signaling pathway ([@B117]); JAK/STAT ([@B144]); RhoA/ROCKs ([@B6]); Notch ([@B159]), and Src/STAT3 ([@B107]).

Despite recent advances in medicine and pharmacy, industrial remedies are not sufficient to prevent the progression of the PH ([@B85]). Therefore, introduction and evaluation of natural compounds effective in the treatment of PH seems necessary.

According to our study, chemical compounds that are effective in treatment of PH include flavonoids, isoflavonoids, monoterpenoid phenolics DMDS, polymethoxylated flavones, terpenoids, phytoesterogens, isoquinoline alkaloids, saponins, polysaccharides, tetracyclic oxindole alkaloid.

All herbs and phytochemicals induce their therapeutic effect through one of the 6 pathways ([**Figure 2**](#f2){ref-type="fig"}):

a.  **Antiproliferation:** Plant extracts and phytochemicals that have antiproliferative effects include *R. tangutica, W. somnifera,* berberine, genistein, isohynchophylline, magnesium lithospemate B, nobiletin, and quercetin, which do their effects by reducing expression or suppressing the pathways involved in cell proliferation. Some of these markers and pathways decreases the expression of cyclin D1, CDK 4 and 6, PP2AC, PDGF-BB, and PCNA markers and increases the p27kip1 (cyclin inhibitor) marker, that suppresses Trk A/ACT and ACT/GSK3b pathways; the final result is reduction of proliferation ([@B45]; [@B48]; [@B69]; [@B22]; [@B84]; [@B98]).

b.  **Antioxidant:** Plant extracts and phytochemicals with antioxidant properties on treatment of PH include *B. vulgaris, C. rhipidophylla, K. odoratissima, M. oleifera, T. arjuna, T. pratense,* carvacrol, magnesium lithospemate B, oxymatrine and resveratrol, which do their effect by increasing CAT, SOD, GPx, GSH levels and reducing H~2~O~2~, ROS, and MDA levels. All of these indicators show decrease oxidative stress and reduce tissue damage ([@B20]; [@B2]; [@B69]; [@B63]; [@B158]; [@B165]; [@B44]; [@B90]; [@B4]).

c.  **Antivascular remodeling:** Vascular remodeling is one of the important events during PH progression that has been explained before. Many plant extracts and phytochemicals do its effects by suppressing ET-1 expression and following that MMP-2 and MMP-9 expression which cause inhibition of the progression of vascular remodeling. Some of these plant extracts and phytochemicals include *C. rhipidophylla, K. odoratissima, S. miltiorrhiza, T. pratense,* asiaticoside, baicalin, ginsenoside Rb1, punicalagin and resveratrol; that have vascular antiremodeling effect and this way inhibit the progression of PH ([@B19]; [@B2]; [@B48]; [@B63]; [@B158]; [@B3]; [@B44]; [@B53]; [@B150]; [@B4]).

d.  **Vasodilator:** One of the important reasons for PH is increased blood vessel contraction and after that PH. The most important vascular relaxation inducers do their effect by increasing NO levels due to increasing eNOS expression and decreasing the levels of TXA2 and cytosolic Ca^2+^. Plant extracts and phytochemicals with these properties include *A macrostemon, A. sativum, E. macrobulbum, K. odoratissima, M. pigra, S. miltiorrhiza, S. securidaca, T. pratense, W. somnifera,* Apple polyphenols, polydatin and resveratrol ([@B34]; [@B19]; [@B115]; [@B69]; [@B2]; [@B63]; [@B47]; [@B55]).

e.  **Apoptosis inducer:** Some of the plant extracts and phytochemicals cause improvement in PH by increasing apoptosis such as *T. arjuna, W. somnifera, apple polyphenols,* baicalin, carvacrol, isohynchophylline, punicalagin, quercetin, resveratrol and salidroside. They act by inhibiting of growth factors such as TGF-β1, AhR and HIF-1α or suppressing PI3K/ACT, ERK1/2/STAT3 pathways, or increase the expression of BAX and caspase-3 (apoptosis inducers) and decrease the expression of BCL2 (anti-apoptosis factor). All of these agents drive the cells (lung tissue cells, PAECs and PASMCs) toward apoptosis and inhibit the progression of PH ([@B45]; [@B56]; [@B69]; [@B147]; [@B48]; [@B165]; [@B44]; [@B90]; [@B55]).

f.  **Anti-inflammation:** One of the notable processes in PH is increased inflammation. Some of the plant extracts and phytochemicals such as *Astragalus polysacharides, W. somnifera*, oxymatrine, punicalagin and resveratrol, can reduce this inflammation by decreasing inflammation factors such as IL-10, IL-6, IL-1β, TNF-α, NFkB, VEGF, pho-IkBα. Therefore, they can inhibit inflammation and following that can reduce the progression of PH ([@B69]; [@B158]; [@B163]).

![The summary of 6 pathways that leads to PH improvement.](fphar-11-00145-g002){#f2}

Future Direction {#s5}
================

The present study provides comprehensive information about medicinal plants and phytochemicals used for PH treatment, as discussed, all these herbs and phytochemicals have therapeutic effects on PH but exert their effects in different ways. There are still unknown mechanisms to industrialization of these medicinal plants and phytochemicals including purification of active compounds of herbs, combining several herbs or phytochemicals to improve their effectiveness (in this case, pharmacological activities, toxicity and herb/food/drug interaction should be completely investigated). Bioinformatics studies are suggested to determine the interaction between active compounds or phytochemicals and their target receptors or target cells. Further studies to identify the signaling pathways are suggested. Making suitable formulations with optimal bioavailability and clinical trials to evaluating the effect of herbs and phytochemicals on patients suffering from PH and investigating the side effects, toxicity, safely and effectiveness of these treatments can provide the field for use in pharmacy.

Conclusion {#s6}
==========

According to this review study, as described, many herbs and natural compounds have the potential for adjuvant therapy of PH treatment without side effects of chemical drugs. In addition, as mentioned, there is no definitive cure for PH, so use of herbs and phytochemicals can help to improve the quality of life in patients with this disorder.
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  5-LOX          5-lipoxygenase
  6-Keto-PGF1α   6-keto prostaglandin F1α
  A~2a~R         adenosine A~2a~ receptor
  α-SMA          α-smooth muscle actin
  ADAMTS-1       a disintegrin and metalloprotease with thrombospondin motif type I
  Ang II         angiotensin II
  AhR            aryl hydrocarbon receptor
  Akt            protein kinase B
  ALK-I          activin receptor like kinase 1
  ALP            alkaline phosphatase
  ALT            alanine amino transferase
  AST            aspartate amino transferase
  BAX            BCL2-associated X protein
  BCL2           B-cell lymphoma-2
  BMPR2          Bone morphogenetic protein type 2 receptor
  BW             body weight
  CAT            catalase
  CAV-I          Caveolin-1
  Cdc2           Cell division control protein 2 homolog 1
  CDK4           cyclin protein kinase 4
  CDK6           cyclin protein kinase 6
  cGMP           Guanosine 3′,5′ cyclic monophosphate
  CTEPH          chronic thromboembolic pulmonary hypertension
  CXCR4          CXC chemokine receptor 4
  DMDS           Dimethyl disulfide
  ECG            electrocardiogram
  ENG            endoglin
  eNOS           endothelial nitric oxide synthase
  ERα            human estrogen receptor sub-type β
  ERβ            human estrogen receptor sub-type β
  ERK1/2         extracellular signal-regulated protein kinases 1 and 2
  ET             endothelin
  ET-1           endothelin-1
  ETAR           endothelin A receptor
  ET-1           endothelin-1
  GSH            glutathione
  GSK3β/β        glycogen synthase kinase 3 beta
  GPx            glutathione peroxidase
  H/L ratio      heterophil to lymphocyte ratio
  HIF-1α         hypoxia-inducible factor 1α
  HIV-1          human immunodeficiency virus type 1
  HO-1           heme oxygenase 1
  HP             Hypoxic pulmonary
  HPASMCs        human pulmonary arterial smooth muscle cells
  HPVECs         human primary vascular endothelial cells
  ICAM-1         intercellular adhesion molecule 1
  IL-10          Interleukin 10
  IL-1β          Interleukin-1β
  IL-6           Interleukin 6
  iNOS           inducible nitric oxide synthase
  %MWT           percentage medial wall thickness of pulmonary arteries
  mCAP           mean carotid artery pressure
  MCT            monocrotaline
  MDA            malondialdehyde
  MMP-2          matrix metalloprotease 2
  MMP-9          matrix metalloprotease 9
  mCAP           mean carotid arterial pressure
  mPAP           mean pulmonary arterial pressure
  mSAP           mean systemic arterial pressure
  MVW            Medial wall thickness
  MWT            medial wall thickness of pulmonary arteries
  ND             not detected
  NF-κB          nuclear factor κB
  NFATc2         calcineurin/nuclear factor of activated T cells c2
  NO             nitric oxide
  NOX            NADPH oxidases
  Nrf 2          nuclear respiratory factor 2
  NRVM           neonatal rat ventricular myocyte
  OPCs           oligometric proanthocyanidins
  OPN            osteopontin
  p27KIP1        Cyclin-dependent kinase inhibitor 1B
  p38            38.000-dalton membrane protein
  p38MAPK        p38 mitogen-activated protein kinase
  p-Akt          phosphorylated Akt
  PA             pulmonary arterial
  PABP           poly-A binding protein
  PAEC           pulmonary arterials endothelial cells
  PAH            pulmonary arterial hypertension
  PAP            pulmonary artery pressure
  PASMC          pulmonary arterial smooth muscle cell
  PBP            pulmonary blood pressure
  PCNA           protein content of proliferating nuclear cell antigen
  PDE            phosphodiesterase enzyme
  PDE5A          Phosphodiesterase type 5A enzyme
  PDGF           platelet derived growth factor
  PGI2           prostaglandin I2
  PHT            pulmonary hypertension
  PI3K           phosphoinositide-3- kinase
  PKA            protein kinase A
  PKB            protein kinase B
  Pim1           provirus integration site for Moloney murine leukemia virus 1
  PNS            Panax notoginseng Saponins
  PP2Ac          protein phosphatase 2A catalytic subunit (Y307)
  PTGS           prostaglandin-endoperoxide synthase
  PVC            pulmonary vascular cell
  PVR            pulmonary vessel resistance
  RES            Resveratrol
  RHF            right heart failure
  ROS            reactive oxygen species
  RV             right ventricle
  RVEF           RV ejection fraction
  RVH            right ventricular hypertrophy
  RVHI           right ventricular hypertrophy index
  RVSP           right ventricular systolic pressure
  RV/ (LV+S)     ratio of right ventricle to the left ventricular plus interventricular septum
  RV/TV ratio    right-to-total ventricular weight ratio
  RV/BW          right ventricle to body weight ratio
  RVP            right ventricular pressure
  S              septum
  SMAD3          SMAD Family Member 3
  SDF-1          stromal cell-derived factor 1
  SOCE           store-operated Ca^2+^ entry
  SPA            small pulmonary arteries
  SM22α          smooth muscle 22α
  SOD-1          superoxide dismutase 1
  Src            Proto-Oncogene, Non-Receptor Tyrosine Kinase
  STAT3          signal transducer and activator of transcription 3
  TAPSE          tricuspid annular plane systolic excursion
  TBARS          thiobarbituric acid reactive substance
  TGF-β1         transforming growth factor 1
  TMS            trimethoxysilbene
  TNF-α          Tumor necrosis factor α
  TrkA           tropomyosin-related kinase A
  Trx-1          thioredoxin reductase 1
  TXA2           thromboxane A2
  TxB2           thromboxane B2
  VCAM-1         vascular cell adhesion molecule 1
  VEF            ventricular ejection fraction
  VEGF           vascular endothelial growth factor
  VEGFA          vascular endothelial growth factor A
  vWF            von Willebrand factor
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